Galectin Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Galectin Therapeutics

27/03/2023 14:24

* Galectin Therapeutics Inc  GALT.OQ   GALT.O  is expected
to show
no change in quarterly revenue when it reports  results on March
29 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Galectin
Therapeutics Inc
is for a loss of 17 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11​, above​ its last closing price
of $1.96. ​​​

This summary was machine generated March 27 at 13:24 GMT.  All
figures in US dollars  unless otherwise stated